

# NYRx BLTG Program Update: Advair

---

## What Pharmacy Providers and Prescribers Need to Know

**Advair HFA® and Advair Diskus®** are subject to the NYRx Brand Less Than Generic program (BLTG). In December 2023, due to market availability issues, NYRx temporarily allowed for generic Advair HFA® and Diskus® to adjudicate without prior authorization (PA) if the brand product was not available from the pharmacy's wholesaler. The manufacturer has confirmed that Advair HFA and Diskus supply issues have resolved, and pharmacies will be able to obtain the supply needed for their NYRx members. Effective **February 28, 2024**, fluticasone/salmeterol HFA and Diskus (generic Advair) will once again require PA. Pharmacies should adjust their inventory and dispense brand Advair HFA® or Advair Diskus® according to the NYRx BLTG program for their NYRx members.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exceptions to this are DAW code "1" and "Brand Medically Necessary" on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

## NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	Epipen, Jr	Rapamune® solution
Advair HFA®	<b>Forteo®</b>	Renvela® tablet, powder pack
Alphagan P® 0.15%	Glumetza®	Restasis®
<b>Alphagan P® 0.1%</b>	Kazano®	Retin-A® cream
Amitiza®	Kitabis® Pak	Ritalin LA®
Apriso®	Kombiglyze® XR	Spiriva® HandiHaler®
Azopt™	Lialda®	Symbicort®
Bethkis®	Nesina®	Tegretol® suspension
Cellcept® suspension	Nexavar®	Tegretol® XR
Combigan®	NuvaRing®	Trileptal® suspension
Copaxone® 20mg SQ	Onglyza®	Vascepa®
Daytrana®	Oseni®	Ventolin® HFA
Depakote® Sprinkle	Pentasa®	<b>Votrient®</b>
Dexilant®	Pradaxa®	Vyvanse® capsule
Dymista®	Protonix® suspension	Vyvanse® chewable tablet
Epipen	Pylera®	Xopenex HFA®
		Zegerid® Rx

\* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

\* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Pharmacy Program Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays, or by email at [NYRxEO@magellanhealth.com](mailto:NYRxEO@magellanhealth.com).

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Office hours are also available by appointment. For more information, email [NYRxEO@magellanhealth.com](mailto:NYRxEO@magellanhealth.com) or visit the [NYRx Education & Outreach website](#).